Illumina, Inc. (ILMN) Expected to Post Earnings of $1.35 Per Share
Wall Street analysts expect that Illumina, Inc. (NASDAQ:ILMN) will announce earnings per share of $1.35 for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Illumina’s earnings, with the highest EPS estimate coming in at $1.47 and the lowest estimate coming in at $1.32. Illumina reported earnings of $1.44 per share during the same quarter last year, which indicates a negative year over year growth rate of 6.2%. The firm is expected to issue its next quarterly earnings results on Tuesday, January 29th.
On average, analysts expect that Illumina will report full year earnings of $5.72 per share for the current fiscal year, with EPS estimates ranging from $5.39 to $5.87. For the next financial year, analysts forecast that the business will report earnings of $6.38 per share, with EPS estimates ranging from $6.07 to $6.83. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Illumina.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million during the quarter, compared to analysts’ expectations of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.11 earnings per share.
Shares of Illumina stock opened at $313.44 on Thursday. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.46 and a quick ratio of 2.24. The stock has a market capitalization of $48.40 billion, a price-to-earnings ratio of 78.36, a PEG ratio of 2.44 and a beta of 1.07. Illumina has a 52-week low of $203.83 and a 52-week high of $372.61.
In related news, EVP Marc Stapley sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $336.68, for a total transaction of $336,680.00. Following the completion of the sale, the executive vice president now directly owns 7,757 shares in the company, valued at $2,611,626.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Francis A. Desouza sold 2,100 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $353.66, for a total transaction of $742,686.00. Following the sale, the insider now owns 75,235 shares of the company’s stock, valued at $26,607,610.10. The disclosure for this sale can be found here. Insiders sold 53,464 shares of company stock valued at $17,883,331 over the last quarter. Company insiders own 0.54% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in ILMN. IFM Investors Pty Ltd grew its position in Illumina by 46.5% during the second quarter. IFM Investors Pty Ltd now owns 6,632 shares of the life sciences company’s stock valued at $1,852,000 after buying an additional 2,104 shares during the period. Cullinan Associates Inc. bought a new stake in Illumina during the second quarter valued at approximately $279,000. Livforsakringsbolaget Skandia Omsesidigt grew its position in Illumina by 93.5% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 4,347 shares of the life sciences company’s stock valued at $1,214,000 after buying an additional 2,100 shares during the period. State of Alaska Department of Revenue grew its position in Illumina by 24.9% during the second quarter. State of Alaska Department of Revenue now owns 23,797 shares of the life sciences company’s stock valued at $6,644,000 after buying an additional 4,747 shares during the period. Finally, Xact Kapitalforvaltning AB grew its position in Illumina by 3.4% during the second quarter. Xact Kapitalforvaltning AB now owns 27,743 shares of the life sciences company’s stock valued at $7,748,000 after buying an additional 918 shares during the period. Institutional investors own 90.13% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Read More: What is an Initial Public Offering (IPO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.